Literature DB >> 35608600

Collaborator Name Misspelled.

.   

Abstract

Entities:  

Year:  2022        PMID: 35608600      PMCID: PMC9131740          DOI: 10.1001/jama.2022.7596

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   157.335


× No keyword cloud information.
  1 in total

1.  Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.

Authors:  Meagan P O'Brien; Eduardo Forleo-Neto; Neena Sarkar; Flonza Isa; Peijie Hou; Kuo-Chen Chan; Bret J Musser; Katharine J Bar; Ruanne V Barnabas; Dan H Barouch; Myron S Cohen; Christopher B Hurt; Dale R Burwen; Mary A Marovich; Elizabeth R Brown; Ingeborg Heirman; John D Davis; Kenneth C Turner; Divya Ramesh; Adnan Mahmood; Andrea T Hooper; Jennifer D Hamilton; Yunji Kim; Lisa A Purcell; Alina Baum; Christos A Kyratsous; James Krainson; Richard Perez-Perez; Rizwana Mohseni; Bari Kowal; A Thomas DiCioccio; Gregory P Geba; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos; David M Weinreich
Journal:  JAMA       Date:  2022-02-01       Impact factor: 157.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.